— Report will be subject of New England CEPAC meeting in March 2020; Open Input now being accepted until August 27, 2019 — BOSTON, August 9, 2019 – The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of crizanlizumab (Novartis) and voxelotor (Global Blood […]
Read More
08/09/2019
— ICER’s ongoing assessment emphasizes that policymakers will need to consider, in addition to traditional measures of clinical effectiveness and cost-effectiveness, that new interventions for sickle cell disease will differentially benefit an historically disadvantaged and underserved community — — Public comment period now open until February 20, 2020; Requests to make oral comment during public […]
Read More
01/23/2020
– Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients; even under favorable modeling assumptions, however, and benefitting from new data from patients and a curated real-world evidence database, the list prices set for crizanlizumab and voxelotor appear too high to align fairly with clinical benefits – – Policymakers […]
Read More
03/12/2020
Public Comments
Closed